VECIMA-NETWORKS
9.5.2024 13:31:32 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) today announced that VECTOR TECH SOLUTIONS is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (EAC) solutions for ASTA-NET, a telecommunications provider in Poland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509796116/en/
The collaboration underscores Vecima’s commitment to expanding its footprint in the European market, with VECTOR TECH SOLUTIONS providing local expertise as a Vecima reseller in Poland. The deployment for ASTA-NET gives the Polish internet and communications technology (ICT) integrator an instant customer success story as it introduces Vecima’s innovative Remote MACPHY Device (RMD) Distributed Access Architecture (DAA) node to the Poland market.
The SC-1D, a cornerstone of the Entra family, is designed to enable operators like ASTA-NET to transition toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability.
Complementing the SC-1D, Vecima’s Entra Access Controller (EAC) serves as a centralized management platform that orchestrates the complex interactions between the core network and distributed access devices. The EAC ensures seamless integration and optimal performance of the DAA ecosystem, facilitating advanced features such as dynamic bandwidth allocation and network virtualization.
ASTA-NET’s adoption of Vecima’s technology through VECTOR TECH SOLUTIONS represents a pivotal step in enhancing its network infrastructure to deliver superior broadband services. With the Entra SC 1-D and EAC, ASTA-NET can position itself at the forefront of digital transformation.
“Collaboration with global broadband technology providers such as Vecima is a great honor,” said Artur Salwach, Sales Managing Director at VECTOR TECH SOLUTIONS. “We are glad we can cooperate with the world's leaders to provide solutions to Polish telecommunications operators such as ASTA-NET and develop their business.”
"Vecima and VECTOR TECH SOLUTIONS are closely aligned in our shared objective of advancing Poland's telecommunications sector," said German Iaryczower, Senior Vice President, Global Sales & Marketing at Vecima. "Our strategic partnership will continue to elevate and expand connectivity throughout Poland.”
For more information about Vecima’s Entra DAA platform, visit vecima.com/network-access/interoperable-daa-solutions.
About ASTA-NET
ASTA-NET, a company of the ASTA Group, present on the market since 1989, a leader in providing telecommunications services in northern Greater Poland and neighboring areas of the West Pomeranian Voivodeship. ASTA-NET covers over 140,000 households and provides services to over 63,000 individual and business clients. Its success is based on bold and permanent investments in network development and product development. The treasure of ASTA-NET is its qualified staff - technology enthusiasts and people focused on customer needs. The company's goal is to be the operator of first choice, i.e. the most desirable provider of multimedia services.
About VECTOR TECH SOLUTIONS
Polish integrator that designs and implements modern ICT solutions, responding to the growing market needs. VECTOR TECH SOLUTIONS supports organizations from various industries, guaranteeing high quality services in the field of optical technologies, uninterrupted power supply, cybersecurity, IT infrastructure and IP networks. The basis for the provided services is a good understanding of clients' business and certified technological knowledge. Everything they have learned over many years while conducting large and complex projects helps adapt their solutions to various and multi-faceted business challenges. Learn more at vectortechsolutions.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509796116/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom